Methadone-nicotine interactions in methadone maintenance treatment patients

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 231-238

  Elkader, Alexander K ^a,b   Brands, Bruna ^a,b,c   Selby, Peter ^a,b,d   Sproule, Beth A ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Office of Research and Surveillance   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Interaction; Methadone; MMT; Nicotine

Indexed keywords

METHADONE; NICOTINE GUM; PLACEBO;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; EUPHORIA; FEMALE; HUMAN; IRRITABILITY; MALE; METHADONE TREATMENT; MULTIPLE CYCLE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; TOBACCO DEPENDENCE;

ADULT; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; NICOTINE; NICOTINIC AGONISTS; OPIOID-RELATED DISORDERS; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 67649243667     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a39113     Document Type: Article

References (56)

1. Berger H, Schweigler M. Smoking characteristics of methadone patients. JAMA. 1972;222:705.
2. Chait LD, Griffiths RR. Effects of methadone on human cigarette smoking and subjective ratings. J Pharmacol Exp Ther. 1984;229:636-640.
3. Stark MJ, Campbell BK. Cigarette smoking and methadone dose levels. Am J Drug Alcohol Abuse. 1993;19:209-217.
4. Clemmey P, Brooner R, Chutuape MA, et al. Smoking habits and attitudes in a methadone maintenance population. Drug Alcohol Depend. 1997;44:123-132.
5. Best D, Lehmann P, Gossop M. Eating too little, smoking and drinking too much: wilder lifestyle problems among methadone maintenance patients. Addict Res. 1998;6:489-498.
6. Richter KP, Gibson CA, Ahluwalia JS, et al. Tobacco use and quit attempts among methadone maintenance clients. Am J Public Health. 2001;91:296-299.
7. Engstrom A, Adamsson C, Allebeck P, et al. Mortality in patients with substance abuse: a follow-up in Stockholm County. 1973-84. Int J Addict. 1991;26:91-106.
8. Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prev Med. 1994;23:61-69.
9. Kozlowski LT, Skinner W, Kent C, et al. Prospects for smoking treatment in individuals seeking treatment for alcohol and other drug problems. Addict Behav. 1989;14:273-278.
10. Frosch DL, Stopshaw S, Jarvik ME, et al. Interest in smoking cessation among methadone maintained outpatients. J Addict Dis. 1998;17:9-19.
11. Clarke JG, Stein MD, McGarry KA, et al. Interest in smoking cessation among injection drug users. Am J Addict. 2001;10:159-166.
12. Frosch DL, Stopshaw S, Nahom D, et al. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Exp Clin Psychopharmacol. 2000;8:97-103.
13. Story J, Stark MJ. Treating cigarette smoking in methadone maintenance clients. J Psychoactive Drugs. 1991;23:205-215.
14. Schmitz JM, Grabowski J, Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend. 1994;34:237-242.
15. Mello NK, Lukas SW, Mendelson JH. Buprenorphine effects on cigarette smoking. Psychopharmacology. 1985;86:417-425.
16. Mutschler NH, Stephen BJ, Teoh SK, et al. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine Tob Res. 2002;4:223-228.
17. Spiga R, Schmitz J, Day J II. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend. 1998;50:157-165.
18. Spiga R, Martinetti MP, Meisch RA, et al. Methadone and nicotine self-administration in humans: a behavioral economic analysis. Psychopharmacology. 2005;178:223-231.
19. McCool RM, Richter KP. Why do so many drug users smoke? J Subst Abuse Treat. 2003;25:43-49.
20. Richter KP, Hamilton AK, Hall S, et al. Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007;15:144-153.
21. Stein MD, Anderson BJ. Nicotine and drug interaction expectancies among methadone maintained cigarette smokers. J Subst Abuse Treat. 2003;24:357-361.
22. Stopshaw S, Rotheram-Fuller E, Yang X, et al. Smoking cessation in methadone maintenance. Addiction. 2002;97:1317-1328.
23. Hukkanen J, Jacob P III, Benowitz N. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
24. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16:36-44.
25. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmcokinetics of methadone. Clin Pharmacokinet. 2002;41:1153-1193.
26. Conte-Devolx B, Oliver C, Giuard P, et al. Effect of nicotine on in vivo secretion of melanocorticotropic hormones in the rat. Life Sci. 1981;28:1067-1073.
27. Marty MY, Erwin VG, Cornell H, et al. Effects of nicotine on beta endorphin, alpha-MSH, and ACTH secretion by isolated perfused mouse brains and pituitary glands. Pharmacol Biochem Behav. 1985;54:317-325.
28. Hexxum TD, Russett LR. Plasma enkephalin-like peptide response to chronic nicotine infusion in guinea pig. Brain Res. 1987;406:370-372.
29. Pierzchala K, Houdi AA, Van Loon GR. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides. 1987;8:1035-1043.
30. Houdi AA, Pierzchala K, Marson L, et al. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides. 1991;12:161-166.
31. Zarrindast M-R, Faraji N, Rostami P, et al. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav. 2003;74:363-369.
32. Berrendero F, Kieffer BL, Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci. 2002;22:10935-10940.
33. Pomerleau OF, Fertig JD, Seyler LW, et al. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology. 1983;81:61-67.
34. Seyler LW, Pomerleau OF, Fertig JD, et al. Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav. 1986;24:159-162.
35. Gorelick DA, Rose J, Jarvick ME. Effect of naloxone on cigarette smoking. J Subst Abuse. 1988;1:153-159.
36. Lerman C, Wileyto EP, Patterson F, et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004;4:184-192.
37. Sheehan DV, Lecrubier Y, Sheehan H, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
38. Heatheron TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127.
39. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
40. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry. 1982;43(12 pt 2):69-74.
41. Haertzen CA, Hill HE, Belleville RE. Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 1963;4:155-166.
42. McNair DM, Lorr M, Droppleman LF. Profile of Mood States Manual. San Diego, Calif: Educational and Industrial Testing Service; 1981.
43. Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
44. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991;86:1467-1476.
45. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289-294.
46. Cardenas L, Tremblay LK, Naranjo CA, et al. Brain reward system activity in major depression and comorbid nicotine dependence. J Pharmacol Exp Ther. 2002;302:1265-1271.
47. Folstein MF, Lurian R. Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med. 1973;2:479-486.
48. Giesbrecht E, Kapsh I, Ferrence R, et al. A sensitive LC/MS/MS method for measuring low concentrations of nicotine metabolites. Ther Drug Monit. 2007;29(4):498.
49. McBride D, Barret SP, Kelly JT, et al. Effects of expectancy and abstinence on the neural response to smoking cues in cigarette smokers: an fMRI study. Neuropsychopharmacology. 2006;31:2728-2738.
50. Davies GM, Wilner P, James DL, et al. Influence of nicotine gum on acute craving for cigarettes. J Psychopharmacol. 2004;18:83-87.
51. Baran-Furga H, Chmielewska K, Bogucka-Bonikowska A, et al. Self-reported effects of methadone on cigarette smoking in methadone-maintained subjects. Subst Use Misuse. 2005;40:1103-1111.
52. Mooney ME, Poling J, Gonzalez G, et al. Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. Am J Addict. 2008;17:287-292.
53. Richter KP, McCool RM, Catley D, et al. Dual pharmacotherapy and motivational interviewing for tobacco dependence. J Addict Dis. 2005;24:79-90.
54. Stein MD, Weinstock MC, Herman DS, et al. A smoking cessation intervention for the methadone-maintained. Addiction. 2006;101:599-607.
55. Stopshaw S, Jarvik ME, Ling W, et al. Contingency management for tobacco smoking in methadone-maintained opiate addicts. Addict Behav. 1996;21:409-412.
56. Russell MAH, Feyerabend C, Cole PV. Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br Med J. 1976;1:1043-1046.